CN110507811A - 一种3d打印卡贝缩宫素舌下口崩片及其制备方法 - Google Patents
一种3d打印卡贝缩宫素舌下口崩片及其制备方法 Download PDFInfo
- Publication number
- CN110507811A CN110507811A CN201910877789.1A CN201910877789A CN110507811A CN 110507811 A CN110507811 A CN 110507811A CN 201910877789 A CN201910877789 A CN 201910877789A CN 110507811 A CN110507811 A CN 110507811A
- Authority
- CN
- China
- Prior art keywords
- carbetocin
- printing
- disintegrating tablet
- oral disintegrating
- binder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108700021293 carbetocin Proteins 0.000 title claims abstract description 43
- NSTRIRCPWQHTIA-DTRKZRJBSA-N carbetocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSCCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(OC)C=C1 NSTRIRCPWQHTIA-DTRKZRJBSA-N 0.000 title claims abstract description 43
- 229960001118 carbetocin Drugs 0.000 title claims abstract description 43
- 238000010146 3D printing Methods 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 22
- 239000011230 binding agent Substances 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000002245 particle Substances 0.000 claims abstract description 7
- 230000008676 import Effects 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000007921 spray Substances 0.000 claims description 8
- 238000007639 printing Methods 0.000 claims description 7
- 238000005507 spraying Methods 0.000 claims description 7
- 230000007480 spreading Effects 0.000 claims description 6
- 238000003892 spreading Methods 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229940069328 povidone Drugs 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000006174 pH buffer Substances 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 9
- 210000004291 uterus Anatomy 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- HPHUVLMMVZITSG-LURJTMIESA-N levetiracetam Chemical compound CC[C@@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-LURJTMIESA-N 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 101800000989 Oxytocin Proteins 0.000 description 2
- 102400000050 Oxytocin Human genes 0.000 description 2
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229960004002 levetiracetam Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940102239 spritam Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pregnancy & Childbirth (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
Abstract
一种3D打印卡贝缩宫素舌下口崩片及其制备方法,它涉及3D打印技术领域。其配方和工艺包含以下步骤:(1)其配方包含以下内容卡贝缩宫素0.1‑50份,黏合剂为50‑99.9份;(2)卡贝缩宫素(颗粒直径应为0.01‑0.1mm)加入3D打印快速成型机的粉末盒中;(3)将黏合剂装入墨盒中;(4)根据预先设定好的参数,建模,并导入3D打印快速成型机的控制系统中;(5)控制系统输出指令,控制3D打印快速成型机打印卡贝缩宫素口崩片;(6)待口崩片黏结和干燥后取出,清扫周围残留粉末,即得。它工艺简单、崩解时间短、起效速度快。
Description
技术领域
本发明涉及3D打印技术领域,具体涉及一种3D打印卡贝缩宫素舌下口崩片及其制备方法。
背景技术
卡贝缩宫素(Carbetocin)是一种合成的具有激动剂性质的长效催产素8肽类似物,其临床和药理特性与天然产生的催产素类似。像催产素一样,卡贝缩宫素与子宫平滑肌的 催产素受体结合,引起子宫的节律性收缩,在原有的收缩基础上,增加其频率和增加子宫张力。在非妊娠状态下,子宫的催产素受体含量很低,在妊娠期间增加,分娩时达高峰。因此卡贝缩宫素对非妊娠的子宫没有作用,但是对妊娠的子宫和刚生产的子宫具有有效的子宫收缩作用。
不论是静脉注射还是肌肉注射卡贝缩宫素后,子宫迅速收缩,可在2分钟内达到一个明确强度。单剂量静脉注射卡贝缩宫素对子宫的活性作用可持续大约1个小时,因此 足以预防刚生产后的产后出血。产后给予卡贝缩宫素后,在收缩的频率与幅度方面都比催产素为长。
研究表明,当硬膜外或腰麻下剖腹产术后立即单剂量静脉给予卡贝缩宫素100μg,在预防子宫张力不足和减少产后出血方面,卡贝缩宫素明显优于安慰剂。在产后的早期给予卡贝缩宫素也可以促进子宫的恢复。
粉液三维印刷(3DP)技术是在上个世纪80年代末由麻省理工学院开发的一种快速成型技术,这种技术采用液体把多层的粉状物黏合在一起形成三维结构。具体的说,该技术先铺设一层薄薄的药粉,然后再在选定区域喷上液滴,液滴与粉末的相互作用会使材料在微观层面上黏结在一起;然后再铺上一层药粉。如此反复进行,直至完成药片的打印。相对传统的压片技术,采用该技术制备的药片具有多孔结构,“就算是一小口水也能使药片快速分散”,从而使药片方便吞咽并快速起效。2015年8月,美国食品和药物管理局(FDA)批准全球首个3D打印药物Spritam(左乙拉西坦,或Levetiracetam)速溶片上市,标志着3D打印成为一种新的制剂加工技术。
舌下口崩片是一种在口腔内不需水即能崩解或溶解的片剂。服用该类制剂时不需用水或只需用少量水,无需咀嚼,片剂置于舌下遇唾液迅速崩解,借舌下吸收进入人体起效。
现有的卡贝缩宫素口服崩解专利CN201580053724的崩解时效未进行有效测定,是否能及时发挥药效尚有疑义。
发明内容
本发明的目的在于针对现有技术的缺陷和不足,提供一种3D打印卡贝缩宫素口崩片及其制备方法,它工艺简单、崩解时间短、起效速度快。
为实现上述目的,本发明采用以下技术方案是,按重量百分比计算,其配方包含以下内容:卡贝缩宫素0.1-50份,黏合剂为50-99.9份。
一种3D打印卡贝缩宫素舌下口崩片的制备方法,包括以下步骤:
(1)卡贝缩宫素加入3D 打印快速成型机的粉末盒中;
(2)将黏合剂装入墨盒中;
(3)根据预先设定好的参数,建模,并导入3D打印快速成型机的控制系统中;
(4)控制系统输出指令,控制3D打印快速成型机打印卡贝缩宫素口崩片:铺粉装置先在粉床上铺一层的药粉,然后在选定区域喷涂黏合剂,为口崩片的第一层,随后铺粉装置铺第二层粉末,如此逐层打印,层层叠加,直至完成口崩片的打印;
(5)待口崩片黏结和干燥后取出,清扫周围残留粉末,即得。
比较好的是,本发明口崩片的三维参数为:直径5-12mm、厚度2-5mm、层数15-50层、层高0.1-0.2mm,黏合剂参数为:喷涂速率3.5-4.5nL×10-14kz、喷涂次数1-3次。
比较好的是,本发明的黏合剂为水、30%~75%乙醇溶液、淀粉浆、聚维酮的水或乙醇溶液。
比较好的是,本发明喷涂的卡贝缩宫素颗粒直径应为0.01-0.1mm。
采用上述技术方案后,本发明有益效果为:采用3D技术打印的卡贝缩宫素口崩片具有工艺简单、崩解速度更快、生物利用度更高、服用更方便等特点,在口腔唾液中即可崩解,而且,相对现有的技术,3D打印技术可以根据患者的个体差异、病证的轻重缓急量身定制适合于患者的剂量,实现个性化给药和精准治疗,从而减少患者服用片数,使药物制剂发挥最大疗效,并使药物毒副作用降到最低。
本文所用的术语“缓冲剂”是指可用于水性体系以讲溶液调整至某一pH(例如,pH5.5-6.5)并且防止该pH变化的物质。缓冲剂一般地选用磷酸盐类,也可以是弱酸或弱碱,其可包含缓冲溶液。缓冲剂是缓冲溶液中负责缓冲作用的物质,通过调节溶液的pH值并阻止pH变化发挥作用。
本文所述的卡贝缩宫素冻干颗粒直径应为0.01-0.1mm,应理解为采用冻干工艺或其他物理加工方式(如研磨、喷雾干燥)或其他物化过程加工方式(如结晶)所能达到的直径。
具体实施方式
本具体实施方式采用的技术方案是:
3D打印卡贝缩宫素舌下口崩片配方包含以下内容:卡贝缩宫素0.1-50份,黏合剂为1-100份。
一种3D打印卡贝缩宫素舌下口崩片的制备方法,包括以下步骤:
(1)卡贝缩宫素加入3D 打印快速成型机的粉末盒中;
(2)将黏合剂装入墨盒中;
(3)根据预先设定好的参数,建模,并导入3D打印快速成型机的控制系统中;
(4)控制系统输出指令,控制3D打印快速成型机打印卡贝缩宫素舌下口崩片:铺粉装置先在粉床上铺一层的药粉,然后在选定区域喷涂黏合剂,为口崩片的第一层,随后铺粉装置铺第二层粉末,如此逐层打印,层层叠加,直至完成口崩片的打印;
(5)待口崩片黏结和干燥后取出,清扫周围残留粉末,即得。
本发明的口崩片三维参数为:直径5-12mm、厚度2-5mm、层数15-50 层、层高0.1-0.2mm,黏合剂参数为:喷涂速率3.5-4.5nL×10-14kz、喷涂次数1-3次。
本发明的的黏合剂为水、30%~75%乙醇溶液、淀粉浆、聚维酮的水或乙醇溶液。
喷涂的卡贝缩宫素颗粒直径应为0.01-0.1mm。
实施例
实施例1
基于配方准备1.0g卡贝缩宫素(颗粒直径0.05mm),配制黏合剂50g,设置3D打印快速成型机的参数为直径8mm、厚度3mm、层数20 层、层高0.15mm,黏合剂参数为:喷涂速率3.5nL×12kz、喷涂次数2次。
按《中国药典》2015年版崩解时限检查法采用崩解仪测定,崩解时限为38秒。
实施例2
基于配方准备1.0g卡贝缩宫素(颗粒直径0.08mm),配制黏合剂10g,设置3D打印快速成型机的参数为直径6mm、厚度4mm、层数40 层、层高0.1mm,黏合剂参数为:喷涂速率4.0nL×13kz、喷涂次数3次。
按《中国药典》2015年版崩解时限检查法采用崩解仪测定,崩解时限为49秒。
以上所述,仅用以说明本发明的技术方案而非限制,本领域普通技术人员对本发明的技术方案所做的其它修改或者等同替换,只要不脱离本发明技术方案的精神和范围,均应涵盖在本发明的权利要求范围当中。
Claims (5)
1.一种3D打印卡贝缩宫素舌下口崩片,其特征在于按重量百分比计算,其配方包含以下内容:卡贝缩宫素0.1-50份,黏合剂为50-99.9份。
2.制备权利要求1所述的3D打印卡贝缩宫素舌下口崩片的方法,其特征在于包括以下步骤:
(1)卡贝缩宫素加入3D 打印快速成型机的粉末盒中;
(2)将黏合剂装入墨盒中;
(3)根据预先设定好的参数,建模,并导入3D打印快速成型机的控制系统中;
(4)控制系统输出指令,控制3D打印快速成型机打印卡贝缩宫素舌下口崩片:铺粉装置先在粉床上铺一层的药粉,然后在选定区域喷涂黏合剂,为口崩片的第一层,随后铺粉装置铺,第二层粉末,如此逐层打印,层层叠加,直至完成口崩片的打印;
(5)待口崩片黏结和干燥后取出,清扫周围残留粉末,即得。
3.根据权利要求2所述的3D打印卡贝缩宫素舌下口崩片的制备方法,其特征在于:所述步骤(3)的参数中,口崩片三维参数为:直径5-12mm、厚度2-5mm、层数15-50 层、层高0.1-0.2mm,黏合剂参数为:喷涂速率3.5-4.5nL×10-14kz、喷涂次数1-3次。
4.根据权利要求2所述的3D打印卡贝缩宫素舌下口崩片的制备方法,其特征在于:所述的黏合剂为水、pH缓冲剂、30%~75%乙醇溶液、淀粉浆、聚维酮的水或乙醇溶液。
5.根据权利要求2所述的3D打印卡贝缩宫素舌下口崩片的制备方法,其特征在于:所述喷涂的卡贝缩宫素颗粒直径应为0.01-0.1mm。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910877789.1A CN110507811A (zh) | 2019-09-17 | 2019-09-17 | 一种3d打印卡贝缩宫素舌下口崩片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910877789.1A CN110507811A (zh) | 2019-09-17 | 2019-09-17 | 一种3d打印卡贝缩宫素舌下口崩片及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110507811A true CN110507811A (zh) | 2019-11-29 |
Family
ID=68632455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910877789.1A Pending CN110507811A (zh) | 2019-09-17 | 2019-09-17 | 一种3d打印卡贝缩宫素舌下口崩片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110507811A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100311655A1 (en) * | 2007-06-07 | 2010-12-09 | Mdrna, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
CN106511285A (zh) * | 2016-09-20 | 2017-03-22 | 南方医科大学 | 一种3d打印灯盏花素口崩片及其制备方法 |
WO2017097194A1 (zh) * | 2015-12-08 | 2017-06-15 | 深圳翰宇药业股份有限公司 | 一种全固相制备卡贝缩宫素的方法 |
CN107106640A (zh) * | 2014-10-01 | 2017-08-29 | 奥克希托恩生物科学公司 | 含有分娩控制物质的口服崩解固体药物剂量单元 |
-
2019
- 2019-09-17 CN CN201910877789.1A patent/CN110507811A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100311655A1 (en) * | 2007-06-07 | 2010-12-09 | Mdrna, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
CN107106640A (zh) * | 2014-10-01 | 2017-08-29 | 奥克希托恩生物科学公司 | 含有分娩控制物质的口服崩解固体药物剂量单元 |
WO2017097194A1 (zh) * | 2015-12-08 | 2017-06-15 | 深圳翰宇药业股份有限公司 | 一种全固相制备卡贝缩宫素的方法 |
CN106511285A (zh) * | 2016-09-20 | 2017-03-22 | 南方医科大学 | 一种3d打印灯盏花素口崩片及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100386391B1 (ko) | 구강내용해형정제및이의제조방법 | |
US10052333B2 (en) | Methods and systems for the delivery of a therapeutic agent | |
Narang et al. | Sublingual mucosa as a route for systemic drug delivery | |
DE602004001209T2 (de) | Schnell wirkende pharmazeutische zusammensetzung | |
EP3267974B1 (en) | A transdermal drug administration device | |
CN105362320B (zh) | 一种3d打印制备速效救心口腔崩解片的方法 | |
CN106511285B (zh) | 一种3d打印灯盏花素口崩片及其制备方法 | |
JPH05500058A (ja) | 経粘膜性剤形 | |
JPS61501150A (ja) | 拡散被覆された複合単位服用剤 | |
ES2658913T3 (es) | Dispositivo de administración transdérmica de un fármaco | |
CN101720219A (zh) | 生产速溶片的方法 | |
BRPI0812064B1 (pt) | formulação farmacêutica na forma de aglomerados, comprimidos, e, processo para a produção de uma formulação farmacêutica | |
CN103491951A (zh) | 用于口吸收的可咀嚼媒介物 | |
CN101678112B (zh) | 用于递送治疗剂的方法和组合物 | |
Takeuchi et al. | A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis | |
TWI513477B (zh) | 快速溶解之藥學組成物(一) | |
HRP20020189A2 (en) | Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction | |
CN106420808A (zh) | 一种含有维生素d3和碳酸钙的制剂及其制备方法 | |
JP2020196753A (ja) | 食道の炎症状態を治療するための最適化された医薬製剤 | |
WO2005094821A1 (fr) | Composition medicale pour augmenter la securite d'un medicament | |
CN110507811A (zh) | 一种3d打印卡贝缩宫素舌下口崩片及其制备方法 | |
CN104644574A (zh) | 一种枸橼酸西地那非掩味制剂 | |
CN1953738A (zh) | 含去氨加压素的泡腾剂 | |
US20070071818A1 (en) | Effervescent formulations comprising apomorphine | |
US20070087054A1 (en) | Effervescent formulations of oxytocin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191129 |